News

In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6 and AdVac-based TB vaccine. The vaccine entered the phase I clinical

The litigation includes the patent infringement suits brought by Tercica and Genentech against Insmed and an unfair business practices suit. The companies agreed that the drug Iplex should

It is intended that the headcount will be reduced from 260 by approximately 15% during this year across the organization. Acambis has appointed a new chief executive officer

ZymoGenetics said the decision would shorten the timeline for offering spray rhThrombin by about 18 months and save substantial amounts of money for the company. ZymoGenetics now plans

The clinical phase II study is a dose-ranging trial to evaluate the efficacy of ABT-894 in attention deficit-hyperactivity disorder (ADHD) patients. The first patients have been enrolled and

Preliminary results from the phase II trial, conducted by Wyeth, showed that the initial formulation of oral methylnaltrexone was generally well tolerated but did not exhibit sufficient clinical

The study conducted in collaboration with Institut Curie will seek to enroll around 20 patients. The goal of this study is to evaluate pharmacokinetic, the safety and the

Despite its failure to provide effectiveness for acute coronary syndrome (ACS), CV said there was no adverse trend in death or arrhythmias in patients on Ranexa. The company

Avalon will use its AvalonRx platform to screen a select set of compounds from Merck's proprietary compound library and identify hits against this target. It has not been